Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $17.25.

ENTA has been the subject of several recent analyst reports. Robert W. Baird dropped their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating for the company in a research report on Tuesday, November 26th. JMP Securities restated a "market outperform" rating and issued a $21.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. StockNews.com raised shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, February 19th. Finally, HC Wainwright restated a "buy" rating and set a $18.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ ENTA traded down $0.18 during mid-day trading on Tuesday, reaching $6.65. The company had a trading volume of 344,775 shares, compared to its average volume of 497,793. Enanta Pharmaceuticals has a one year low of $4.71 and a one year high of $17.80. The business's 50-day simple moving average is $6.19 and its 200 day simple moving average is $8.73. The firm has a market cap of $141.86 million, a price-to-earnings ratio of -1.34 and a beta of 0.48.

Remove Ads

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. On average, sell-side analysts anticipate that Enanta Pharmaceuticals will post -4.65 EPS for the current year.

Insider Activity at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly purchased 45,000 shares of the firm's stock in a transaction dated Wednesday, February 12th. The stock was bought at an average price of $5.69 per share, with a total value of $256,050.00. Following the completion of the purchase, the chief executive officer now owns 846,638 shares in the company, valued at approximately $4,817,370.22. This represents a 5.61 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 13.89% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. acquired a new position in shares of Enanta Pharmaceuticals in the 4th quarter worth approximately $26,000. Tower Research Capital LLC TRC lifted its holdings in Enanta Pharmaceuticals by 46.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after buying an additional 2,274 shares during the period. US Bancorp DE boosted its position in Enanta Pharmaceuticals by 4,933.7% during the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 4,243 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Enanta Pharmaceuticals during the 4th quarter worth about $58,000. Finally, Squarepoint Ops LLC bought a new position in shares of Enanta Pharmaceuticals in the 4th quarter worth about $66,000. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.